Lenzo, N., Capp, A., Patel, N., Wheatcroft, M., Cade, D. (2025). CUPID (
            <sup>64</sup>
            Cu-TLX592 phase I PK, biodistribution and dosimetry): A proof-of-concept study of TLX592 targeted alpha therapy in prostate cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e17023